Stage 3 chronic kidney disease
Pro Research Analysisby 
Searched over 200M research papers
Prevalence and Global Burden of Stage 3 Chronic Kidney Disease
Stage 3 chronic kidney disease (CKD) is highly prevalent worldwide, representing the majority of CKD cases and affecting a significant portion of the adult population. Global studies estimate that about 7.6% of people have stage 3 CKD, making it the most common stage of the disease . In the United States, the prevalence of stage 3 and 4 CKD has stabilized in recent years, with about 6.9% of adults affected . Similar prevalence rates are observed in other countries, with studies from Europe, Asia, and the Americas confirming that stage 3 CKD is widespread and often underdiagnosed 1457.
High Rates of Undiagnosed Stage 3 CKD
A major concern is the high proportion of people with stage 3 CKD who remain undiagnosed. Large multinational studies show that over 60% to 95% of patients with laboratory evidence of stage 3 CKD do not have a formal diagnosis recorded in their medical records 1457. This underdiagnosis is especially common among older adults, women, and even those with known risk factors such as diabetes, hypertension, and cardiovascular disease 145. The lack of diagnosis means many patients miss out on early interventions that could slow disease progression and reduce complications 456.
Disease Progression, Risks, and Outcomes in Stage 3 CKD
Stage 3 CKD is the first stage that can be identified with a simple blood test, and it is associated with increased risks of all-cause mortality and cardiovascular disease compared to people without CKD 38. However, the risk of progression to end-stage renal disease is relatively low, with less than 20% of patients experiencing significant kidney function decline over five years and only about 4% progressing to end-stage disease over ten years . The risk of death, especially from cardiovascular causes, is higher in those with more advanced stage 3 CKD (stage 3b) compared to those with milder stage 3a disease .
Comorbidities and the Need for Early Intervention
Many patients with stage 3 CKD have other medical conditions, such as diabetes and hypertension, which increase their risk of disease progression and complications 25. A subset of patients with stage 3 CKD and these comorbidities (sometimes called "CKD stage 3-plus") have healthcare costs and disease progression rates similar to those with more advanced CKD, suggesting they may benefit from earlier referral to kidney specialists and more intensive management .
Gaps in Monitoring and Management
Despite clinical guidelines recommending regular monitoring and management of kidney function and risk factors in stage 3 CKD, real-world data show that most patients do not receive adequate follow-up or treatment, especially if their CKD is not formally diagnosed . This gap in care highlights the need for better detection and proactive management to improve outcomes and slow disease progression 456.
Clinical Practice Guidelines for Stage 3 CKD
Guidelines recommend against routine screening for CKD in adults without risk factors, but they do advise using medications such as ACE inhibitors or angiotensin II receptor blockers for patients with hypertension and stage 1 to 3 CKD . Statin therapy is also recommended to manage cholesterol in these patients . Early identification and management are key to reducing cardiovascular risks and preventing further kidney damage .
Conclusion
Stage 3 CKD is common and often goes undiagnosed, especially among older adults, women, and those with other health conditions. While the risk of progression to kidney failure is low for most, the risk of death—particularly from heart disease—is higher than in the general population. Early detection, better monitoring, and targeted management for high-risk patients are essential to improve outcomes and reduce the burden of CKD worldwide 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic